Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 905681 in Advanced Solid Tumours
NCT04147247Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2019
- Primary completion
- May 2021
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 905681 in solid tumor (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose (MTD)/Optimal Biological Dose (OBD) and Number of Patients Experiencing Adverse Events (AEs) up to 126 days. Started Dec 2019; status: completed.
02
Drugs
BI 905681
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04147247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147247.